Last week, pharmaceutical giant Eli Lilly (LLY -1.45%) announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouse Novo Nordisk (NVO -3.50%)? Health-care analyst Max Macaluso discusses these topics in the following video.